BBIO BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.…
Industry Peers
BiotechnologyKey Statistics
About BridgeBio Pharma (NASDAQ: BBIO)
›
BridgeBio Pharma (NASDAQ: BBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,081 employees.
The shares were at 78.18 USD on 19 November 2026, up 24.6% over 52 weeks. Its 52-week range is 60.55 USD to 93.42 USD: the price is 16.3% below the high and 29.1% above the low.
Its market capitalisation is 15.23B USD.
BridgeBio Pharma reports return on equity of 34.7%, an operating margin of -37.3% and revenue up 192.6% year over year.
Its debt exceeds its cash by 1.84B USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 107.00 USD is 36.9% above the current price. The next earnings report is expected on 23 February 2027.